Back

Cardiac resynchronization therapy outcomes by patient sex and baseline QRS duration: insights from AdaptResponse

11 May 2026 (13:30 - 14:15)
Organised by: Logo
Congress Presentation Part of: Evolving electrophysiological therapies: implantable cardioverter-defibrillator and cardiac resynchronisation therapy Cardiac Resynchronisation Therapy (CRT) HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Mr Bart Gerritse

Maastricht (Netherlands (The))

5 More presentations in this session

Presentation thumbnail
Novel echocardiography-derived haemodynamic forces analysis in cardiac resynchronization therapy: response prediction and long-term prognosis
Doctor R. Tarantini (Utrecht, NL)
Abstract Slides
Presentation thumbnail
Optimizing beta-blocker dosage in female patients using the wearable cardioverter defibrillator: the OPT-BB Women interventional study
Professor V. Kutyifa (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Refining patient selection for CRT: the role of true LBBB morphology in CRT response
Doctor J. Simoes De Azevedo Massa Pereira (Faro, PT)
Abstract Slides Video
Presentation thumbnail
Frontal QRS-T angle identifies non-responders to cardiac resynchronisation therapy even among ideal candidates with heart failure
Doctor B. Yencilek (Ankara, TR)
Abstract Slides Video
Presentation thumbnail
Appropriate device therapies after CRT-D implantation in the modern heart failure treatment era
Doctor I. Martins Moreira (Vila Real, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Evolving electrophysiological therapies: implantable cardioverter-defibrillator and cardiac resynchronisation therapy

The Event

Event poster

Heart Failure 2026

11 May 2026 13:30 CET
You may be interested in
thumbnail
Congress Presentation
Cardiac resynchronization therapy: better in women?
thumbnail
Congress Presentation
Cardiac resynchronization therapy: better in women?
thumbnail
Congress Presentation
Synchronized left ventricular pacing improves cardiac resynchronization therapy outcomes: insights from AdaptResponse

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources